Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis

A. Ponyi, T. Constantin, Z. Balogh, Z. Szalai, G. Borgulya, K. Molnǎr, I. Tefner, M. Garami, G. Fekete, K. Dankó

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: Our aim is to present the disease course, frequency of relapses and survival of juvenile and adult dermatomyositis (JDM/DM) patients. Methods: Analysis was performed using data on 73 patients. The median follow-up for 38 JDM patients was 32 months and 78 months for 35 adult DM patients. Results: 23/38 JDM patients (60%) had monophasic, 12/38 (31.6%) had polycyclic and 3/38 (7.9%) had chronic disease. Among children treated only with glucocorticoids, 12/20 (60%) had monophasic and 8/20 (40%) had polycyclic disease. 10/17 (58.8%) children, who required second-line immunosuppressive agents, had monophasic and 4/17 (23.5%) had polycyclic disease. 18/35 DM (51.4%) patients had monophasic, 13/35 (37.1%) had polycyclic, 1/35 (2.9%) had chronic disease and 3/35 (8.6%) had fulminant myositis. Among DM patients requiring only glucocorticoids, 12/20 (60%) were monophasic and 8/20 (40%) were polycyclic. In patients requiring second-line immunosuppressive agents, 6/15 patients (40%) had monophasic and 5/15 (33.3%) had polycyclic disease. Among patients with polycyclic disease, the risk of relapse was higher during first year than later in the disease course. None of the JDM patients have died, while 4 disease-specific deaths occurred in adult patients. There was no significant difference between the survival of JDM and DM patients. Discussion: There was no correlation between relapse-free survival and the initial therapeutic regimen. Many of our patients had polycyclic or chronic disease. As relapses can occur after a prolonged disease-free interval, patients should be followed for at least 2 years. Although we found a favourable survival rate, further investigations are needed to assess functional outcome.

Original languageEnglish
Pages (from-to)50-56
Number of pages7
JournalClinical and Experimental Rheumatology
Volume23
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Dermatomyositis
Recurrence
Survival
Chronic Disease
Immunosuppressive Agents
Glucocorticoids
Myositis

Keywords

  • Disease course
  • Juvenile and adult dermatomyositis
  • Relapse risk
  • Survival analysis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

@article{4cb1ecca512b4f2b916aa81ed465ad39,
title = "Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis",
abstract = "Objective: Our aim is to present the disease course, frequency of relapses and survival of juvenile and adult dermatomyositis (JDM/DM) patients. Methods: Analysis was performed using data on 73 patients. The median follow-up for 38 JDM patients was 32 months and 78 months for 35 adult DM patients. Results: 23/38 JDM patients (60{\%}) had monophasic, 12/38 (31.6{\%}) had polycyclic and 3/38 (7.9{\%}) had chronic disease. Among children treated only with glucocorticoids, 12/20 (60{\%}) had monophasic and 8/20 (40{\%}) had polycyclic disease. 10/17 (58.8{\%}) children, who required second-line immunosuppressive agents, had monophasic and 4/17 (23.5{\%}) had polycyclic disease. 18/35 DM (51.4{\%}) patients had monophasic, 13/35 (37.1{\%}) had polycyclic, 1/35 (2.9{\%}) had chronic disease and 3/35 (8.6{\%}) had fulminant myositis. Among DM patients requiring only glucocorticoids, 12/20 (60{\%}) were monophasic and 8/20 (40{\%}) were polycyclic. In patients requiring second-line immunosuppressive agents, 6/15 patients (40{\%}) had monophasic and 5/15 (33.3{\%}) had polycyclic disease. Among patients with polycyclic disease, the risk of relapse was higher during first year than later in the disease course. None of the JDM patients have died, while 4 disease-specific deaths occurred in adult patients. There was no significant difference between the survival of JDM and DM patients. Discussion: There was no correlation between relapse-free survival and the initial therapeutic regimen. Many of our patients had polycyclic or chronic disease. As relapses can occur after a prolonged disease-free interval, patients should be followed for at least 2 years. Although we found a favourable survival rate, further investigations are needed to assess functional outcome.",
keywords = "Disease course, Juvenile and adult dermatomyositis, Relapse risk, Survival analysis",
author = "A. Ponyi and T. Constantin and Z. Balogh and Z. Szalai and G. Borgulya and K. Molnǎr and I. Tefner and M. Garami and G. Fekete and K. Dank{\'o}",
year = "2005",
month = "1",
language = "English",
volume = "23",
pages = "50--56",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1",

}

TY - JOUR

T1 - Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis

AU - Ponyi, A.

AU - Constantin, T.

AU - Balogh, Z.

AU - Szalai, Z.

AU - Borgulya, G.

AU - Molnǎr, K.

AU - Tefner, I.

AU - Garami, M.

AU - Fekete, G.

AU - Dankó, K.

PY - 2005/1

Y1 - 2005/1

N2 - Objective: Our aim is to present the disease course, frequency of relapses and survival of juvenile and adult dermatomyositis (JDM/DM) patients. Methods: Analysis was performed using data on 73 patients. The median follow-up for 38 JDM patients was 32 months and 78 months for 35 adult DM patients. Results: 23/38 JDM patients (60%) had monophasic, 12/38 (31.6%) had polycyclic and 3/38 (7.9%) had chronic disease. Among children treated only with glucocorticoids, 12/20 (60%) had monophasic and 8/20 (40%) had polycyclic disease. 10/17 (58.8%) children, who required second-line immunosuppressive agents, had monophasic and 4/17 (23.5%) had polycyclic disease. 18/35 DM (51.4%) patients had monophasic, 13/35 (37.1%) had polycyclic, 1/35 (2.9%) had chronic disease and 3/35 (8.6%) had fulminant myositis. Among DM patients requiring only glucocorticoids, 12/20 (60%) were monophasic and 8/20 (40%) were polycyclic. In patients requiring second-line immunosuppressive agents, 6/15 patients (40%) had monophasic and 5/15 (33.3%) had polycyclic disease. Among patients with polycyclic disease, the risk of relapse was higher during first year than later in the disease course. None of the JDM patients have died, while 4 disease-specific deaths occurred in adult patients. There was no significant difference between the survival of JDM and DM patients. Discussion: There was no correlation between relapse-free survival and the initial therapeutic regimen. Many of our patients had polycyclic or chronic disease. As relapses can occur after a prolonged disease-free interval, patients should be followed for at least 2 years. Although we found a favourable survival rate, further investigations are needed to assess functional outcome.

AB - Objective: Our aim is to present the disease course, frequency of relapses and survival of juvenile and adult dermatomyositis (JDM/DM) patients. Methods: Analysis was performed using data on 73 patients. The median follow-up for 38 JDM patients was 32 months and 78 months for 35 adult DM patients. Results: 23/38 JDM patients (60%) had monophasic, 12/38 (31.6%) had polycyclic and 3/38 (7.9%) had chronic disease. Among children treated only with glucocorticoids, 12/20 (60%) had monophasic and 8/20 (40%) had polycyclic disease. 10/17 (58.8%) children, who required second-line immunosuppressive agents, had monophasic and 4/17 (23.5%) had polycyclic disease. 18/35 DM (51.4%) patients had monophasic, 13/35 (37.1%) had polycyclic, 1/35 (2.9%) had chronic disease and 3/35 (8.6%) had fulminant myositis. Among DM patients requiring only glucocorticoids, 12/20 (60%) were monophasic and 8/20 (40%) were polycyclic. In patients requiring second-line immunosuppressive agents, 6/15 patients (40%) had monophasic and 5/15 (33.3%) had polycyclic disease. Among patients with polycyclic disease, the risk of relapse was higher during first year than later in the disease course. None of the JDM patients have died, while 4 disease-specific deaths occurred in adult patients. There was no significant difference between the survival of JDM and DM patients. Discussion: There was no correlation between relapse-free survival and the initial therapeutic regimen. Many of our patients had polycyclic or chronic disease. As relapses can occur after a prolonged disease-free interval, patients should be followed for at least 2 years. Although we found a favourable survival rate, further investigations are needed to assess functional outcome.

KW - Disease course

KW - Juvenile and adult dermatomyositis

KW - Relapse risk

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=20144384248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144384248&partnerID=8YFLogxK

M3 - Article

C2 - 15789887

AN - SCOPUS:20144384248

VL - 23

SP - 50

EP - 56

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 1

ER -